Efficacy of switching from premixed insulin to insulin glargine regimen in Type 2 diabetes mellitus patients with different islet functions

Yang Y, Yao JJ, Du JL, et al: Primary prevention of macroangiopathy in patients with short-duration type 2 diabetes by intensified multifactorial intervention: seven-year follow-up of diabetes complications in Chinese. Diabetes Care. 36:978–984. 2013.

Gaede P, Lund-Andersen H, Parving HH and Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 358:580–591. 2008. View Article : Google Scholar : PubMed/NCBI

Holman RR, Paul SK, Bethel MA, Matthews DR and Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 359:1577–1589. 2008.PubMed/NCBI

Rizvi AA and Ligthelm RJ: The use of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: advantages and limitations. Insulin. 2:68–79. 2007. View Article : Google Scholar

Miser WF, Arakaki R, Jiang H, Scism-Bacon J, Anderson PW and Fahrbach JL: Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Clin The. 32:896–908. 2010.

Levit S, Toledano Y and Wainstein J: Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes. Int J Clin Pract. 65:165–171. 2011. View Article : Google Scholar

Vaag A and Lund SS: Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol. 66:159–170. 2012. View Article : Google Scholar

Fritsche A, Larbig M, Owens D and Häring HU; the GINGER study group. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab. 12:115–123. 2010. View Article : Google Scholar : PubMed/NCBI

Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A and Esposito K: Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes: Meta-analysis of randomized controlled trials. Diabetes Care. 34:510–517. 2011.

Hammer H and Klinge A: Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. Int J Clin Pract. 61:2009–2018. 2007. View Article : Google Scholar

Bu S, Guo XH, Yang WY, et al: Post-hoc analyses of type 2 diabetes patients switch from premixed insulin regimen to basal insulin plus oral hypoglycemic agents regimen. Zhong Hua Yi Xue Za Zhi. 87:3115–3118. 2007.(In Chinese).

Davies M, Lavalle-González F, Storms F and Gomis R; AT, LANTUS Study Group. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes Metab. 10:387–399. 2008. View Article : Google Scholar

Gómez-Peralta F, Carramiñana-Barrera F, Félix-Redondo FJ and Fraile-Gómez J; Extreme Rescue Study Group. Glycaemic control in patients with type 2 diabetes switching from premixed insulin to long-acting basal insulin analogue plus oral antidiabetic drugs: an observational study. Int J Clin Pract. 66:959–968. 2012.PubMed/NCBI

Yang W, Lv X, Li Q, Jia W and Tian H: A prospective study to optimize insulin treatment by switching to insulin glargine in type 2 diabetic patients previously uncontrolled on premixed insulin: the optimization study. Curr Med Res Opin. 28:533–541. 2012. View Article : Google Scholar

Li X, Zhou ZG, Qi HY, Chen XY and Huang G: Replacement of insulin by fasting C-peptide in modified homeostasis model assessment to evaluate insulin resistance and islet beta cell function. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 29:419–423. 2004.(In Chinese).

Ligthelm RJ, Gylvin T, DeLuzio T and Raskin P: A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study. Endocr Pract. 17:41–50. 2011. View Article : Google Scholar

Standl E, Maxeiner S, Raptis S, Karimi-Anderesi Z and Schweitzer MA; HOE901/4009 Study Group. Good glycemic control with flexibility in timing of basal insulin supply: a 24-week com-parison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care. 28:419–420. 2005. View Article : Google Scholar

Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA and Yki-Järvinen H: Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 28:254–259. 2005. View Article : Google Scholar : PubMed/NCBI

Porcellati F, Lucidi P, Rossetti P, et al: Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus. Diabetes Care. 34:2521–2523. 2011. View Article : Google Scholar : PubMed/NCBI

Nathan DM, Buse JB, Davidson MB, et al: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 32:193–203. 2009. View Article : Google Scholar

Romero-Márquez RS, Díaz-Veja G and Romero-Zepeda H: Style and quality of life in patients with type 2 diabetes. Rev Med Inst Mex Seguro Soc. 49:125–136. 2011.(In Spanish).

Shrestha P and Ghimire L: A review about the effect of life style modification on diabetes and quality of life. Glob J Health Sci. 4:185–190. 2012.PubMed/NCBI